Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
8650884 | American Heart Journal | 2018 | 30 Pages |
Abstract
Harmony Outcomes will assess the CV safety of albiglutide in patients with T2DM and CV disease. Trials of other agents in the glucagon-like peptide-1 receptor agonist class have shown CV benefit for only some of these medications, possibly due to differences in trial design or instead due to differences in drug structure or metabolism. Harmony Outcomes will provide information critical to our understanding of this heterogenous class of glucose-lowering agents.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Jennifer B. MD, Adrian F. MD, Ralph B. Sr, PhD, Chris B. MD, Salim MB, BS, Nigel P. MA, Lawrence A. MD, Drusilla BSc, Rachael BSc, Kristina MA, MS, Stefano MD, John J.V. BSc, MB, ChB, MD,